Skip to main content

Table 1 Baseline demographic and clinical characteristics in the overall study population; in the central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) samples; and in the treatment naïve and previously treated patients

From: Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant

Variable

Overall (n = 57)

CRVO (n = 15)

BRVO (n = 42)

P*

Naïve (n = 31)

Previously treated (n = 26)

P*

Type of RVO, n (%)

 CRVO

15 (26.3)

N.A.

N.A.

N.A.

9 (21.0)

6 (23.1)

0.7647

 BRVO

42 (73.7)

22 (71.0)

20 (76.9)

Treatment status, n (%)

 Naïve

31 (54.4)

9 (60.0)

22 (52.4)

0.7647a

N.A.

N.A.

N.A.

 Previously treated

26 (45.6)

6 (40.0)

20 (47.6)

Age, years

 Mean (SD)

72.4 (9.3)

70.6 (9.1)

73.0 (9.4)

0.3994

72.3 (10.5)

72.5 (7.9)

0.8225

 95% CI

69.9 to 74.9

65.6 to 75.7

70.1 to 76.0

68.4 to 76.1

69.3 to 75.7

Sex, n (%)

 Women

34 (59.6)

10 (66.7)

24 (57.1)

0.5224

19 (61.3)

15 (57.7)

0.7846

 Men

23 (40.4)

5 (33.3)

18 (42.9)

12 (38.7)

11 (42.3)

Eye, n (%)

 Right

25 (43.9)

5 (33.3

20 (47.6)

0.3428

14 (45.2)

11 (42.3)

0.8303

 Left

32 (56.1)

10 (66.7)

22 (52.4)

17 (54.8)

15 (57.7)

NOII

 Mean (SD)

1.3 (1.7)

1.1 (1.5)

1.4 (1.8)

0.5850

0.0

2.9 (1.4)

< 0.0001

 95% CI

0.8 to 1.8

0.2 to 1.9

0.8 to 1.9

0.0 to 0.0

2.3 to 3.4

Type of RVO-ME, n (%)

 SLRS

2 (3.5)

1 (6.7)

1 (2.4)

0.3056b

2 (6.5)

0 (0.0)

0.1474b

 CME

20 (35.1)

3 (20.0)

17 (40.5)

6 (19.4)

14 (53.8)

 SRD

35 (61.4)

11 (73.3)

24 (57.1)

23 (74.2)

12 (46.2)

Duration of RVO-ME, days

 Mean (SD)

61.3 (81.6)

60.7 (70.8)

61.5 (85.9)

0.8632

62.5 (94.3)

59.9 (65.2)

0.5424

 95% CI

39.7 to 83.0

21.5 to 99.9

34.8 to 84.3

27.9 to 97.1

33.6 to 86.2

BCVA**

 Mean (SD)

55.2 (19.4)

55.5 (15.7)

55.1 (20.7)

0.6738

55.0 (19.0)

55.5 (20.3)

0.7524

 95% CI

50.1 to 60.4

46.8 to 64.2

48.7 to 61.6

48.1 to 62.0

47.3 to 63.7

 

CRT, μm

 Mean (SD)

567.6 (226.2)

549.8 (158.7)

573.9 (247.3)

0.8420

617.7 (280.0)

507.9 (117.1)

0.2846

 95% CI

507.6 to627.6

461.9 to 637.7

496.9 to 651.0

515.0 to 720.4

460.6 to 555.1

NMCST500, μm

 Mean (SD)

175.1 (53.6)

180.2 (53.0)

173.7 (54.3)

0.6570

180.2 (54.6)

169.1 (52.8)

0.3610

 95% CI

160.9 to 189.4

150.9 to 209.5

156.4 to 190.3

160.2 to 200.2

147.8 to 190.4

NMCST1500, μm

 Mean (SD)

180.6 (58.4)

188.3 (60.6)

177.9 (78.1)

0.5742

183.5 (58.9)

177.2 (58.7)

0.5859

 95% CI

165.1 to 196.1

154.7 to 221.8

159.8 to 196.0

161.9 to 205.1

153.5 to 200.9

TMCST500, μm

 Mean (SD)

189.6 (76.5)

205.5 (118.5)

183.9 (55.4)

0.9278

186.4 (65.5)

193.5 (89.1)

0.6137

 95% CI

169.3 to 209.9

139.8 to 275.1

166.7 to 201.2

162.3 to 210.4

157.5 to 229.4

TMCST1500, μm

 Mean (SD)

184.1 (56.5)

194.1 (75.7)

180.5 (48.4)

0.5804

189.2 (61.4)

178.0 (50.4)

0.2866

 95% CI

169.1 to 199.1

152.1 to 236.0

165.5 to 195.6

166.7 to 211.8

157.6 to 198.4

CST, μm

 Mean (SD)

184.1 (57.0)

184.1 (67.3)

184.1 (53.7)

0.9494

186.8 (54.6)

180.8 (60.6)

0.5749

 95% CI

169.0 to 199.2

146.9 to 221.4

167.3 to 200.8

166.8 to 206.9

156.3 to 205.3

HRF, n (%)

  <  10

16 (28.1)

3 (20.0)

13 (31.0)

0.3247b

8 (25.8)

8 (30.8)

0.5098b

 10–20

23 (40.4)

11 (73.3)

12 (28.6)

12 (38.7)

11 (42.3)

  > 20

18 (31.6)

1 (6.7)

17 (40.5)

11 (35.5)

7 (26.9)

DRIL, n (%)

 Yes

34 (59.6)

10 (66.7)

24 (57.1)

0.5582a

20 (64.5)

14 (53.8)

0.4323a

 No

23 (40.4)

5 (33.3)

18 (42.9)

 

11 (35.5)

12 (46.2)

Cysts volume, μm3

 Mean (SD)

317.9 (145.4)

285.7 (121.8)

329.7 (152.8)

0.3268

318.9 (154.6)

316.9 (137.1)

0.9084

 95% CI

279.0 to 356.9

218.2 to 353.1

281.5 to 378.0

261.2 to 376.6

261.5 to 372.2

Cysts, n (%)

  <  100 μm

2 (3.6)

1 (6.7)

1 (2.4)

0.2838b

1 (3.3)

1 (3.8)

0.4658b

 100–200 μm

12 (21.4)

5 (33.3)

7 (17.1)

8 (26.7)

4 (15.4)

  > 200 μm

42 (75.0)

9 (60.0)

33 (80.5)

21 (70.0)

21 (80.8)

ELM, n (%)

 Non-disrupted

13 (22.8)

2 (13.3)

11 (26.2)

0.2059b

5 (16.1)

8 (30.8)

0.6727b

 Partially disrupted

24 (42.1)

6 (40.0)

18 (42.9)

16 (51.6)

8 (30.8)

 Disrupted

20 (35.1)

7 (46.7)

13 (31.0)

10 (32.39

10 (38.5)

SRF, n (%)

 Yes

35 (61.4)

11 (73.3)

24 (57.1)

0.3600a

23 (74.2)

12 (46.2)

0.0548a

 No

22 (38.6)

4 (26.7)

18 (42.9)

8 (25.8)

14 (53.8)

SRF, μm

 Mean (SD)

147.1 (112.2)

103.8 (38.8)

166.9 (129.0)

0.1097

158.4 (129.6)

125.3 (67.1)

0.3943

 95% CI

108.5 to 185.6

77.8 to 129.9

112.4 to 221.4

102.3 to 214.4

82.7 to 168.0

  1. RVO Retinal vein occlusion, CRVO Central retinal vein occlusion, BRVO Branch retinal vein occlusion, NA Not applicable, SD Standard deviation, 95% CI 95% Confidence interval, NOII Number of intravitreal injections, RVO retinal vein occlusion, ME macular edema, SLRS Sponge-like retinal swelling, CME Cystoid macular edema, SRD Serous retinal detachment, CRT Central retinal thickness, NMCST Nasal mean choroidal subfoveal thickness, TMCST Temporal mean choroidal subfoveal thickness, 500 ring of 500 μm, 1500 Ring of 1500 μm, CST Choroidal subfoveal thickness, HRF Hyperreflective foci, DRIL Disorganization of retinal inner layers, ELM External limiting membrane, SRF Serous retinal fluid
  2. aFisher exact test
  3. bChi-squared from trend test
  4. *Mann-Whitney test
  5. **Letters in the Early Treatment Diabetic Retinopathy Study (ETDRS) charts